Allison Florance

2.8k total citations · 1 hit paper
30 papers, 2.1k citations indexed

About

Allison Florance is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Infectious Diseases. According to data from OpenAlex, Allison Florance has authored 30 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 4 papers in Infectious Diseases. Recurrent topics in Allison Florance's work include Cancer Treatment and Pharmacology (18 papers), HER2/EGFR in Cancer Research (17 papers) and Advanced Breast Cancer Therapies (14 papers). Allison Florance is often cited by papers focused on Cancer Treatment and Pharmacology (18 papers), HER2/EGFR in Cancer Research (17 papers) and Advanced Breast Cancer Therapies (14 papers). Allison Florance collaborates with scholars based in United States, United Kingdom and Peru. Allison Florance's co-authors include Lisa O’Rourke, Stephen Johnston, J. Maltzman, John Pippen, Michael F. Press, Xavier Pivot, Mark D. Pegram, Henry Gómez, Steven Stein and Alexey Manikhas and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Allison Florance

29 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer

2009 766 citations Stephen Johnston, John Pippen et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Allison Florance United States	16	1.5k	754	492	397	297	30	2.1k
Rasim Gucalp United States	24	1.1k 0.7×	628 0.8×	124 0.3×	116 0.3×	269 0.9×	87	1.7k
Pablo J. Cagnoni United States	25	1.2k 0.9×	830 1.1×	100 0.2×	321 0.8×	412 1.4×	51	2.5k
Ingo Schmidt‐Wolf Germany	20	2.7k 1.8×	717 1.0×	98 0.2×	557 1.4×	570 1.9×	73	3.6k
William L. Read United States	18	1.6k 1.1×	1.1k 1.4×	73 0.1×	184 0.5×	633 2.1×	53	2.5k
Hiroichi Ishikawa Japan	23	717 0.5×	1.1k 1.5×	191 0.4×	125 0.3×	284 1.0×	132	2.0k
É. Lemarié France	22	929 0.6×	1.1k 1.5×	70 0.1×	109 0.3×	334 1.1×	105	1.9k
María José Bento Portugal	20	979 0.7×	599 0.8×	102 0.2×	326 0.8×	427 1.4×	79	1.8k
Taimur Sher United States	24	993 0.7×	341 0.5×	131 0.3×	133 0.3×	795 2.7×	124	2.1k
Jean‐Christophe Vaillant France	21	1.7k 1.2×	794 1.1×	119 0.2×	303 0.8×	345 1.2×	60	3.1k
Saul Yanovich United States	23	887 0.6×	579 0.8×	84 0.2×	94 0.2×	382 1.3×	47	2.0k

Countries citing papers authored by Allison Florance

Since Specialization

Citations

This map shows the geographic impact of Allison Florance's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Allison Florance with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Allison Florance more than expected).

Fields of papers citing papers by Allison Florance

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Allison Florance. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Allison Florance. The network helps show where Allison Florance may publish in the future.

Co-authorship network of co-authors of Allison Florance

This figure shows the co-authorship network connecting the top 25 collaborators of Allison Florance. A scholar is included among the top collaborators of Allison Florance based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Allison Florance. Allison Florance is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Finn, Richard S., Michael F. Press, Judy Dering, et al.. (2013). Quantitative ER and PgR Assessment as Predictors of Benefit from Lapatinib in Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Metastatic Breast Cancer. Clinical Cancer Research. 20(3). 736–743. 20 indexed citations

Holmes, Frankie A., Virginia Espina, Lance A. Liotta, et al.. (2013). Pathologic complete response after preoperative anti-HER2 therapy correlates with alterations in PTEN, FOXO, phosphorylated Stat5, and autophagy protein signaling. BMC Research Notes. 6(1). 507–507. 50 indexed citations

Esteva, Francisco J., Sandra Franco, Abenaa M. Brewster, et al.. (2013). An Open-Label Safety Study of Lapatinib Plus Trastuzumab Plus Paclitaxel in First-Line HER2-Positive Metastatic Breast Cancer. The Oncologist. 18(6). 661–666. 15 indexed citations

Blackwell, Kimberly, Harold J. Burstein, Anna Maria Storniolo, et al.. (2012). Overall Survival Benefit With Lapatinib in Combination With Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Final Results From the EGF104900 Study. Journal of Clinical Oncology. 30(21). 2585–2592. 411 indexed citations

Roder, Joanna, Heinrich Röder, Julia Grigorieva, et al.. (2011). S1-4: Retrospective Analysis of Study EGF30008 by Mass-Spectrometry Based Serum Assay (VeriStrat®).. Cancer Research. 71(24_Supplement). S1–4. 2 indexed citations

Nagarwala, Yasir M., Virginia Espina, L. A. Liotta, et al.. (2011). Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy.. Journal of Clinical Oncology. 29(15_suppl). 506–506. 37 indexed citations

Johnston, S., et al.. (2011). OT1-02-03: EGF114299: Safety and Efficacy of an Aromatase Inhibitor (AI) in Combination with Lapatinib (L), Trastuzumab (T) or Both for the Treatment of Hormone Receptor-Positive (HR+), HER2+ Metastatic Breast Cancer (MBC).. Cancer Research. 71(24_Supplement). OT1–2. 1 indexed citations

Schwartzberg, Lee S., Sandra Franco, Allison Florance, et al.. (2010). Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor–Positive Metastatic Breast Cancer. The Oncologist. 15(2). 122–129. 158 indexed citations

Franco, Sandra, et al.. (2010). Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor–Positive Metastatic Breast Cancer. The Oncologist. 15(3). 327–327. 13 indexed citations

10.

Kumar, Princy, Anthony LaMarca, Edwin DeJesus, et al.. (2009). A randomized, controlled trial of initial anti-retroviral therapy with abacavir/lamivudine/zidovudine twice-daily compared to atazanavir once-daily with lamivudine/zidovudine twice-daily in HIV-infected patients over 48 weeks (ESS100327, the ACTION Study). AIDS Research and Therapy. 6(1). 3–3. 16 indexed citations

11.

Johnston, Stephen, John Pippen, Xavier Pivot, et al.. (2009). Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor–Positive Metastatic Breast Cancer. Journal of Clinical Oncology. 27(33). 5538–5546. 766 indexed citations breakdown →

12.

Finn, RS, MF Press, Judy Dering, et al.. (2009). Progression-free survival (PFS) of patients with HER2-negative, estrogen-receptor (ER)-low metastatic breast cancer (MBC) with the addition of lapatinib to letrozole: Biomarker results of EGF30008. Journal of Clinical Oncology. 27(15_suppl). 1018–1018. 12 indexed citations

13.

O’Shaughnessy, J., K. L. Blackwell, Harold J. Burstein, et al.. (2008). A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. Journal of Clinical Oncology. 26(15_suppl). 1015–1015. 109 indexed citations

14.

Ross, Lisa, Ronan Boulmé, Jaime E. Hernández, et al.. (2005). A Direct Comparison of Drug Susceptibility to HIV Type 1 from Antiretroviral Experienced Subjects as Assessed by the Antivirogram and PhenoSense Assays and by Seven Resistance Algorithms. AIDS Research and Human Retroviruses. 21(11). 933–939. 16 indexed citations

15.

Ross, Lisa, Ronan Boulmé, Gregory Fusco, Anthony Scarsella, & Allison Florance. (2005). Comparison of HIV Type 1 Protease Inhibitor Susceptibility Results in Viral Samples Analyzed by Phenotypic Drug Resistance Assays and by Six Resistance Algorithms: An Analysis of a Subpopulation of the CHORUS Cohort. AIDS Research and Human Retroviruses. 21(8). 696–701. 7 indexed citations

16.

Sosa, Néstor, Christina Hill‐Zabala, Edwin DeJesus, et al.. (2005). Abacavir and Lamivudine Fixed-Dose Combination Tablet Once Daily Compared With Abacavir and Lamivudine Twice Daily in HIV-Infected Patients Over 48 Weeks (ESS30008, SEAL). JAIDS Journal of Acquired Immune Deficiency Syndromes. 40(4). 422–427. 32 indexed citations

17.

Herrington, David M., Timothy D. Howard, Allison Florance, et al.. (2001). Estrogen Receptor Polymorphisms Associated With Enhanced Response of HDL to Estrogen Replacement Therapy in Postmenopausal Women. Circulation. 103(suppl_1). 1353–1353.

18.

Ely, E. Wesley, et al.. (1999). Large Scale Implementation of a Respiratory Therapist– driven Protocol for Ventilator Weaning. American Journal of Respiratory and Critical Care Medicine. 159(2). 439–446. 204 indexed citations

19.

Cheville, N. F., Steven C. Olsen, Allen E. Jensen, et al.. (1996). Effects of age at vaccination on efficacy of Brucella abortus strain RB51 to protect cattle against brucellosis. American Journal of Veterinary Research. 57(8). 1153–1156. 83 indexed citations

20.

Cheville, N. F., Steven C. Olsen, A. E. Jensen, et al.. (1996). Bacterial persistence and immunity in goats vaccinated with a purE deletion mutant or the parental 16M strain of Brucella melitensis. Infection and Immunity. 64(7). 2431–2439. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact